Table 3. Factors associated with antibody response by univariate, multivariate and propensity score analysis.
Univariate Analysis | Multivariate logistic regression | Propensity score Analysis | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Variables | OR | 95% CI | P | Variables | OR | 95% CI | P | Variables | aOR | 95% CI | P |
Age (Per 10-year increase) | 0.66 | 0.60–0.82 | <0.001 | Age (Per year increase) | 0.61 | 0.48–0.78 | <0.001 | Steroids | 0.64 | 0.28–1.50 | 0.31 |
Female gender | 1.34 | 0.88–2.04 | 0.17 | BMI | 1.06 | 1.00–1.13 | 0.06 | MPA | 0.17 | 0.07–0.41 | <0.001 |
Ethnicity | 1.16 | 0.87–1.54 | 0.32 | MPA | 0.02 | 0.01–0.11 | <0.001 | Triple IS | 0.96 | 0.34–2.73 | 0.94 |
BMI (Per 1mg/kg2) | 1.03 | 0.99–1.06 | 0.18 | Steroid | 0.27 | 0.04–1.97 | 0.20 | Vaccine (AZD1222 vs BNT162b2) | 0.93 | 0.41–2.13 | 0.87 |
Diabetes | 0.82 | 0.53–1.27 | 0.39 | CNI | 0.20 | 0.02–2.39 | 0.21 | ||||
CVD | 0.58 | 0.36–0.93 | 0.03 | Time since transplantation/y | 1.05 | 0.98–1.12 | 0.19 | ||||
Primary renal disease | 1.07 | 0.96–1.18 | 0.22 | BK Viremia | 2.58 | 0.83–8.02 | 0.10 | ||||
Time since transplantation/y | 1.09 | 1.06–1.14 | <0.001 | eGFR α, β | 1.40 | 1.19–1.66 | <0.001 | ||||
Cancer | 0.75 | 0.33–1.70 | 0.49 | Vaccine (AZD1222 vs BNT162b2) | 0.58 | 0.30–1.13 | 0.11 | ||||
CNI | 0.35 | 0.13–0.95 | 0.04 | Number of IS | 1.64 | 0.25–10.73 | 0.60 | ||||
MPA | 0.10 | 0.06–0.20 | <0.001 | ||||||||
Steroid | 1.53 | 0.99–2.36 | 0.06 | ||||||||
Number of IS | 0.58 | 0.39–0.86 | 0.007 | ||||||||
eGFR α, β | 1.12 | 1.01–1.25 | 0.03 | ||||||||
eGFR ≥ 30 α | 1.10 | 0.64–1.91 | 0.73 | ||||||||
eGFR ≥ 60 α | 1.90 | 1.16–3.09 | 0.01 | ||||||||
Donor type | 0.99 | 0.64–1.51 | 0.95 | ||||||||
BK virus | 2.50 | 1.17–5.33 | 0.02 | ||||||||
CMV | 0.68 | 0.35–1.31 | 0.25 | ||||||||
EBV | 0.67 | 0.30–1.50 | 0.33 | ||||||||
Acute rejection | 2.37 | 1.28–4.38 | 0.006 | ||||||||
Vaccine (AZD1222 vs BNT162b2) | 0.76 | 0.46–1.27 | 0.29 |
α, the Modification of Diet in Renal Disease eGFR;
β, per 10 ml/min/1.73m2 increase; AZD1222, Oxford/AstraZeneca vaccine; aOR, adjusted odds ratio; BMI, body mass index; BNT162b2, Pfizer-BioNTech vaccine; CI, confidence interval; CMV, cytomegalovirus; CNI, calcineurin inhibitor; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; EBV, Epstein bar virus; IS, immunosuppression; MPA, mycophenolic acid; MDRD, modification of diet in renal disease, OR, odds ratio; y, year